Evgen Pharma PLC has been granted a patent by the US Patent & Trademark Office covering its lead product, SFX-01. Evgen Pharma said the patent extends and reinforces the intellectual property in relation to sulforaphane, the naturally occurring compound on which SFX-01 is based.
Evgen is current undertaking two phase II trials of the product, one in advanced breast cancer, and one in subarachnoid haemorrhages.
“The ongoing expansion of our intellectual property position is a central tenet of our commercialisation strategy. With regard to SFX-01, we now have granted intellectual property in the US relating to the composition of the active pharmaceutical ingredient and the processes for manufacturing. As we move forward, we expect further developments with the potential to yield a third tier of patent protection around SFX-01,” said Chief Executive Officer Stephen Franklin in a statement.
See the article in full at LSE.co.uk